UroGen Pharma’s Roller Coaster Ride: Can They Bounce Back?
UroGen Pharma recently missed analyst expectations, reporting quarterly revenue at US$20 million, 11% below forecasts, with an earnings per share loss of US$0.92, 18% under projections. Analysts still predict a…